Chapter 1. Industry Overview of CVD Prevention
1.1 Definition and Scope
1.1.1 Definition of CVD Prevention
1.1.2 Market Segmentation
1.1.3 Years Considered for the Study
1.1.4 Assumptions and Acronyms Used
1.1.4.1 Market Assumptions and Market Forecast
1.1.4.2 Acronyms Used In Global CVD Prevention Market
1.2 Summary
1.2.1 Executive Summery
1.2.2 CVD Prevention Market By Product Type
1.2.3 Global CVD Prevention Market By Application
1.2.4 Global CVD Prevention Market by Regions
Chapter 2. Research Approach
2.1 Methodology
2.1.1 Research Programs/By Resolution Type
2.1.2 Market Size Estimation
2.1.3 Market Breakdown and Data Triangulation
2.2 Data Source
2.2.1 Secondary Sources
2.2.2 Primary Sources
Chapter 3. Market Dynamics and Competition Analysis
3.1 Market Drivers
3.1.1 Driver 1
3.1.2 Driver 2
3.2 Restraints and Challenges
3.2.1 Restraint 1
3.2.2 Restraint 2
3.3 Growth Opportunities
3.3.1 Opportunity 1
3.3.2 Opportunity 2
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Threat of Substitute
3.4.4 Threat of New Entrants
3.4.5 Degree of Competition
3.5 Market Concentration Ratio And Market Maturity Analysis of CVD Prevention Market
3.5.1 Go To Market Strategy
3.5.1.1 Introduction
3.5.1.2 Growth
3.5.1.3 Maturity
3.5.1.4 Saturation
3.5.1.5 Possible Development
3.6 Technological Roadmap for CVD Prevention Market
3.7 Value Chain Analysis
3.7.1 List of Key Manufacturers
3.7.2 List of Customers
3.7.3 Level of Integration
3.8 Regulatory Compliance
3.9 Competitive Landscape, 2019
3.9.1 Player Positioning Analysis
3.9.2 Key Strategies Adopted By Leading Players
Chapter 4. CVD Prevention Market By Product Type
4.1 Introduction
4.2 Global CVD Prevention Revenue (US$ Mn) by Product Type
4.2.1 Global CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 – 2027
4.2.2 DETECTION & DIAGNOSIS
4.2.2.1 DETECTION & DIAGNOSIS Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.2.2.1.1 Artificial intelligence in cardiovascular imaging
4.2.2.1.1.1 Artificial intelligence in cardiovascular imaging Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.2.2.1.2 In vitro diagnostics at point-of-care
4.2.2.1.2.1 In vitro diagnostics at point-of-care Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.2.3 REMOTE PATIENT MONITORING
4.2.3.1 REMOTE PATIENT MONITORING Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.2.3.1.1 Wearable technology for remote patient monitoring
4.2.3.1.1.1 Wearable technology for remote patient monitoring Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.2.3.1.2 Non-wearable technology for remote patient monitoring
4.2.3.1.2.1 Non-wearable technology for remote patient monitoring Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.2.4 TREATMENT
4.2.4.1 TREATMENT Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.2.4.1.1 Anti-hypertensives
4.2.4.1.1.1 Anti-hypertensives Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.2.4.1.2 Anti -dyslipidemia drugs
4.2.4.1.2.1 Anti-dyslipidemia drugs Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.2.4.1.3 Anti-thrombotic drugs
4.2.4.1.3.1 Anti-thrombotic drugs Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
4.3 Market Attractive Analysis By Product Type 2019
Chapter 5. CVD Prevention Market By Application
5.1 Introduction
5.2 Global CVD Prevention Revenue (US$ Mn) by Application
5.2.1 Global CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 – 2027
5.2.2 Hospital
5.2.2.1 Hospital Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
5.2.3 Home Health Care
5.2.3.1 Home Health Care Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
5.2.4 Ambulatory Care
5.2.4.1 Ambulatory Care Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
5.2.5 Speciality Clinics
5.2.5.1 Speciality Clinics Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
5.2.6 Others
5.2.6.1 Others Market Revenue (US$ Mn) and Growth Rate (%), 2016 - 2027
5.3 Market Attractive Analysis By Application 2019
Chapter 6. North America CVD Prevention Market By Country
6.1 North America CVD Prevention Market Overview
6.2 U.S.
6.2.1 U.S. CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
6.2.2 U.S. CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
6.3 Canada
6.3.1 Canada CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
6.3.2 Canada CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
6.4 North America PEST Analysis
Chapter 7. Europe CVD Prevention Market By Country
7.1 Europe CVD Prevention Market Key Overview
7.2 UK
7.2.1 UK CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
7.2.2 UK CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
7.3 Germany
7.3.1 Germany CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
7.3.2 Germany CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
7.4 France
7.4.1 France CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
7.4.2 France CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
7.5 Spain
7.5.1 Spain CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
7.5.2 Spain CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
7.6 Rest of Europe
7.6.1 Rest of Europe CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
7.6.2 Rest of Europe CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
7.7 Europe PEST Analysis
Chapter 8. Asia-Pacific CVD Prevention Market By Country
8.1 Asia Pacific CVD Prevention Market Overview
8.2 China
8.2.1 China CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
8.2.2 China CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
8.3 Japan
8.3.1 Japan CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
8.3.2 Japan CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
8.4 India
8.4.1 India CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
8.4.2 India CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
8.5 Australia
8.5.1 Australia CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
8.5.2 Australia CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
8.6 South Korea
8.6.1 South Korea CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
8.6.2 South Korea CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
8.7 Rest of Asia-Pacific
8.7.1 Rest of Asia Pacific CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
8.7.2 Rest of Asia Pacific CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
8.8 Asia Pacific PEST Analysis
Chapter 9. Latin America CVD Prevention Market By Country
9.1 Latin America CVD Prevention Market Overview
9.2 Brazil
9.2.1 Brazil CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
9.2.2 Brazil CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
9.3 Mexico
9.3.1 Mexico CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
9.3.2 Mexico CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
9.4 Rest of Latin America
9.4.1 Rest of Latin America CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
9.4.2 Rest of Latin America CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
9.5 Latin America PEST Analysis
Chapter 10. Middle East & Africa CVD Prevention Market By Country
10.1 Middle East & Africa CVD Prevention Market Overview
10.2 Saudi Arabia
10.2.1 Saudi Arabia CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
10.2.2 Saudi Arabia CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.3 UAE
10.3.1 UAE CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
10.3.2 UAE CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.4 Rest of Middle East & Africa
10.4.1 Rest of Middle East & Africa CVD Prevention Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
10.4.2 Rest of Middle East & Africa CVD Prevention Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.5 Middle East & Africa PEST Analysis
Chapter 11. Player Analysis of CVD Prevention
11.1 Global CVD Prevention Market Company Share Analysis
11.2 Competition Matrix
11.2.1 Competitive Benchmarking of key players by price, presence, market share, and R&D investment
11.2.2 New Product Launches and Product Enhancements
11.2.3 Mergers And Acquisition In Global CVD Prevention Market
11.2.4 Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
Chapter 12. Company Profile
12.1 AstraZeneca plc
12.1.1 Company Snapshot
12.1.2 Business Overview
12.1.3 Financial Overview
12.1.3.1 Revenue (US$ Mn), 2019
12.1.3.2 AstraZeneca plc 2019 CVD Prevention Business Regional Distribution
12.1.4 Product/Service and Specifications
12.1.5 Recent Development & Business Strategy
12.1.6 Manufacturing Plant Footprint Analysis
12.2 Boehringer Ingelheim GmbH
12.3 MyoKardia
12.4 Novartis
12.5 Roche Holding AG.
12.6 Sanofi S.A.
12.7 Takeda Pharmaceutical Company Limited
12.8 United Therapeutics Corporation
12.9 Others
The market for CVD prevention is expected to reach a market value of around US$ 258.4 Bn by 2027.
The CVD prevention market is expected to grow at a CAGR of around 5.8% from 2020 to 2027.
The rapidly increasing cases of cardiovascular disease (CVD) across the globe, need for the prevention, the major economic burden of CVD on countries, and high prevalence of high blood pressure, high cholesterol, and smoking across the globe are some of the factors driving the market growth.
AstraZeneca plc, Boehringer Ingelheim GmbH, MyoKardia, Novartis, Roche Holding AG., Sanofi S.A., Takeda Pharmaceutical Company Limited, United Therapeutics Corporation, and others are the prominent players in the market.
North America held the highest market share in the CVD prevention market.
Asia Pacific is expected to be the fastest growing market over the forecast period.
In end-user segment the hospital segment is growing at faster pace.
Customer Satisfaction
Availability - we are always there when you need us
Fortune 50 Companies trust Acumen Research and Consulting
of our reports are exclusive and first in the industry
more data and analysis
reports published till date